Loading chat...
IN SB0351
Bill
AI Summary
-
Opioid treatment programs must periodically and randomly test patients for methadone, cocaine, opiates, amphetamines, barbiturates, tetrahydrocannabinol, benzodiazepines, and any other suspected drugs of abuse, including before treatment begins.
-
Programs must administer at least 16 drug tests per 12-month period for each patient during treatment.
-
All tests must be conducted in an observed manner to prevent sample tampering.
-
Patients testing positive for unauthorized controlled substances or illegal drugs must undergo a clinical evaluation by the onsite physician within 10 days and cannot take home medications until passing a subsequent random test.
-
Patients with positive tests must report daily to the facility and take weekly random tests until passing a test, with the physician determining when daily treatment is no longer necessary.
Legislative Description
Testing opioid treatment program patients. Requires that an opioid treatment program periodically and randomly test a patient for certain drugs at least 16 times during each 12 month period during the patient's treatment by the program.
Last Action
First reading: referred to Committee on Health & Provider Services
1/7/2016